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Myeloid apolipoprotein E controls dendritic cell
antigen presentation and T cell activation
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Cholesterol homeostasis has a pivotal function in regulating immune cells. Here we show that
apolipoprotein E (apoE) deﬁciency leads to the accumulation of cholesterol in the cell
membrane of dendritic cells (DC), resulting in enhanced MHC-II-dependent antigen pre-
sentation and CD4+ T-cell activation. Results from WT and apoE KO bone marrow chimera
suggest that apoE from cells of hematopoietic origin has immunomodulatory functions,
regardless of the onset of hypercholesterolemia. Humans expressing apoE4 isoform (ε4/3–
ε4/4) have increased circulating levels of activated T cells compared to those expressing WT
apoE3 (ε3/3) or apoE2 isoform (ε2/3–ε2/2). This increase is caused by enhanced antigen-
presentation by apoE4-expressing DCs, and is reversed when these DCs are incubated with
serum containing WT apoE3. In summary, our study identiﬁes myeloid-produced apoE as a
key physiological modulator of DC antigen presentation function, paving the way for further
explorations of apoE as a tool to improve the management of immune diseases.
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Cellular and systemic metabolism regulates the physiologi-cal and pathological functions of lymphocytes and othersubsets of leukocytes1,2. Several lines of evidence indicate a
key role of cholesterol in the regulation of immune responses
which are not only associated with an increased demand for
membrane synthesis during cell expansion, but also relate to the
ability of cholesterol to engage type I interferon signaling3. This
effect, in turn, supports cytotoxic T-cell effector function4 and
promotes lymphocyte proliferation induced by antigen-
presenting dendritic cells5. Cholesterol is also a key constituent
of lipid rafts, specialized microdomains of the cell membrane
where, among others, toll-like receptors (TLRs), major histo-
compatibility complex (MHC) molecules, T-cell receptor (TCR)
and B-cell receptor (BCR) are enriched6–8. Changes in cholesterol
content modify raft-dependent signaling due to protein deloca-
lization and impact immune cell functions9–12. Low cellular
cholesterol content activates sterol receptor element binding
protein (SREBP), a transcription factor which controls the
expression of genes involved in cholesterol biosynthesis and
uptake13,14. In contrast, the last step precursors of cholesterol
biosynthesis, such as desmosterol, or products of cholesterol
oxidation such as oxysterols, inhibit SREBP activity and activate
liver X receptors (LXR) to favor cholesterol elimination from
cells. Of note, LXR signaling has been proposed to couple sterol
metabolism to T-cell proliferation in the adaptive immune
responses. Indeed, LXR dependent ATP-binding cassette sub-
family G member 1 (ABCG1), promoting cholesterol efﬂux from
cells to lipoproteins, limits T-cell proliferation15. Vice versa
intracellular cholesterol accumulation, as a consequence of
ABCA1 and ABCG1 deﬁciency results in leukocytosis and the
expansion of progenitor cell populations in mice16.
Classically, hypercholesterolemia has been indicated as the driver
of such metabolic alterations occurring in immune cells. ApoE
KO or LDLR KO mice fed an atherogenic diet develop pronounced
hypercholesterolemia and display an immune-activated phenotype
characterized by increased T-effector memory cells, which mimics
the proﬁle observed in hypercolesterolemic patients17. In the same
experimental settings, the overexpression of apolipoprotein A-I
(apoA-I), which increases the ability to transport cholesterol back to
the liver, results in a reduced cellular cholesterol accumulation and
immune cell activation in lymph nodes18,19. These data point to a
critical role for apolipoproteins, including apoA-I and apoE, in
controlling cholesterol immunometabolism at both a systemic and
cellular level.
ApoA-I is mainly synthesized by the liver and the intestine,
while apoE derives mainly from the liver, but is also produced by
myeloid cells20. While hepatic derived apoE is associated to very
low density lipoprotein (VLDL) and contributes to their catabo-
lism, leading to atherosclerosis in apoE KO mice, myeloid-derived
apoE is present on nascent HDL. Of note, apoE is also found on
the surface of hematopoietic stem and multipotent progenitor
cells (HSPCs) in a proteoglycan-bound pool, where it appears to
control cell proliferation in an ABCA1- and ABCG1-dependent
fashion, causing monocytosis in apoE KO mice21. Moreover,
apoE was reported to modulate neutrophil and macrophage
activation22,23, worsening the prognosis of Listeria monocytogenes
or Klebsiella pneumoniae infections24, to facilitate lipid antigen
presentation by CD1 molecules to natural killer T cells (NKT)25
and to increase susceptibility to experimental autoimmune
encephalomyelitis26. ApoE KO mice showed increased T-cell
inﬁltration of the vascular wall27 and increased circulating levels
of T-effector memory cells17, pointing to an increased activation
of the adaptive immune response as a result of apoE deﬁciency.
However, the molecular mechanisms leading to the immuno-
modulatory role of apoE on adaptive immunity has not been fully
elucidated.
Here we investigate the immunomodulatory role of apoE with
a major focus on the regulation of cholesterol homeostasis in cells
involved in the adaptive immune response. Our results from
experimental models and humans reveal a critical function of
myeloid-derived apoE in controlling DC antigen presentation and
T-cell priming. They further indicate that this apoE function is
mediated through the autocrine/paracrine modulation of cho-
lesterol metabolism in DCs, and is independent of systemic
hypercholesterolemia.
Results
ApoE deﬁciency boosts CD4± T-cell-mediated immune
response. An initial assessment of the immune phenotype of
apoE KO mice revealed that these mice display splenomegaly
(Fig. 1a, b) with an accumulation of CD4+CD44hiCD62Llo T cells
(effector memory, TEM) but not of CD8+CD44hiCD62Llo in the
spleen (Fig. 1c, d and Supplementary Figure 1A), and a con-
comitant decrease of CD4+CD44loCD62Lhi T cells (Tnaive). In
addition, the proportion of activated CD44hiCXCR3hi CD4+, but
not of CD8+ T cells increased in the spleen of apoE KO mice
compared to their WT counterparts (Fig. 1e and Supplementary
Figure 1B). A similar proﬁle was observed in the blood and in
peripheral lymph nodes (Supplementary Figure 1C-H). No sig-
niﬁcant differences in CD4+CD44hiCD62Lhi (central memory,
TCM) (Fig. 1c, d) and in CD4+CD25hiFOXP3+ T-regulatory cells
(Treg) (Supplementary Figure 2A) were observed in the circula-
tion and in secondary lymphoid organs between WT and apoE
KO mice. To investigate the physiological relevance of this phe-
notype, we analyzed the survival of B6Kd-derived skin grafts
transplanted onto WT and apoE KO mice (Fig. 1f), an allor-
esponse mediated by both CD8+ and CD4+ T cells28. As the
impact of apoE deﬁciency was mainly observed on CD4+ T cells,
all recipients received a depleting anti-CD8 antibody prior to
transplantation29 to transiently remove the CD8+-mediated
response and allow activation of CD4+ T cells with indirect
allospeciﬁcity. ApoE deﬁciency led to signiﬁcantly faster allograft
rejection (Fig. 1g), increased CD4+ T cells in the draining lymph
nodes, expansion of CD4+CD44hi and CD4+CD44hiCXCR3hi
cells (Fig. 1h–j) and polarization toward CD4+ TEM cells (Sup-
plementary Figure 3A). In line with these observations, T cells
isolated from lymph nodes of apoE KO mice had an increased
migratory capacity towards CXCL10 (Fig. 1k), which stimulates
the migration of CXCR3+ effector T cells30 when compared to
wild-type T cells. In contrast, there was no difference in migration
towards CCL19 and CCL21, which stimulates the migration of
CCR7+ naive and TCM cells31 (Fig. 1l) and in basal migration
(Supplementary Figure 3B). These data indicate that apoE deﬁ-
ciency results in enhanced CD4+ T-cell proliferation and biased
differentiation toward an effector memory phenotype.
Hematopoietic-derived apoE regulates CD4± T-cells activation.
ApoE is a component of certain plasma lipoproteins and mediates
lipoprotein catabolism in the liver, mainly by binding the VLDL-
receptor, the LDL-receptor and the apoE2 receptor on the
hepatocyte surface32,33. Therefore, apoE deﬁciency is associated
with a decreased catabolism of atherogenic lipoproteins thus
favoring hypercholesterolemia and atherosclerosis
development34,35. We and others have shown that hypercholes-
terolemia induces systemic inﬂammation, which is reﬂected in
increased circulating T-effector cells in mice and in
humans17,36,37. Therefore, the phenotype observed in apoE KO
mice might results from systemic inﬂammation driven by dysli-
pidemia. To address this possibility, we transplanted B6Kd-
derived skin allografts onto WT or apoE KO mice that had been
lethally irradiated and reconstituted with bone marrow (BM)
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from either apoE KO or WT mice (Fig. 2a). Rejection of allo-
geneic skin grafts by WT and apoE KO mice transplanted with
apoE KO BM was signiﬁcantly faster compared to that of WT BM
recipients (Fig. 2b). Plasma cholesterol levels in WT mice trans-
planted with apoE KO BM were similar to those of apoE KO mice
transplanted with WT BM, as was cholesterol distribution in the
different lipoprotein subclasses (VLDL, LDL and HDL) (Fig. 2c, d
and Supplementary Figure 4A), ruling out the possibility that
faster rejection was simply the consequence of hypercholester-
olemia. Accordingly, apoE KO mice, independently of the BM
transplanted, displayed increased levels of CD4+ TEM, CD4
+CD25+ and CD4+CD44hi activated T cells (usually associated
with inﬂammation17,38) in the circulation as well as in draining
and non-draining lymph nodes and in the spleen (Supplementary
Figure 4B-G). This proﬁle mirrored the immuno-inﬂammatory
response associated to hypercholesterolemia and conﬁrmed that
allogenic skin graft rejection was independent of the systemic
metabolic environment, suggesting a mechanism dependent on
leukocyte-produced apoE. To validate this hypothesis, T cells
isolated from peripheral lymph nodes of WT BM to WT
mice, WT BM to apoE KO or from apoE KO BM to WT were
challenged with splenocytes from B6Kd donor mice. Alloreactive
CD4+Ki67+ (proliferating) and polarized CD4+TEM but not
CD8+Ki67+ nor CD8+TEM cells were signiﬁcantly increased in
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Fig. 1 ApoE deﬁciency promotes CD4+ T-cell activation and skin allograft rejection. a–b Representative images (a) and percentage of spleen weight
corrected for body weight (b) from WT and apoE KO mice. c–d Frequency of CD4+ (c) and CD8+ (d) T-cells subsets in the spleen of WT and apoE KO
mice. e Frequency of CD4+ and CD8+ activated CD44hi CXCR3+ T cells in the spleen of WT and apoE KO mice. f Graphic representation of a typical skin
allograft transplantation experiment: a piece of tail skin from C57BL/6Kd donor was transplanted on the back of WT or apoE KO mice and graft
survival was scored up to 3 weeks. g Graft survival following skin allotransplantation. Survival of less than 50% of the donor skin was recorded as rejection.
h Number of CD4+ T cells inﬁltrating the lymph nodes (axillary and brachial) draining (dLNs) and (contra-lateral inguinal) non-draining (ndLNs) the graft,
corrected for LNs weight. i–j Number of activated CD4+ T cells CD44hi (i) and CD44hi CXCR3+ (j) in the dLNs after allograft rejection; representative dot
plots are shown. k–lMigratory response of T lymphocytes isolated from draining lymph nodes, after allograft rejection, to the chemokines CXCL10 (k) and
CCL19/21 (l) measured by transwell. N= 4 (g–l) or 6 (a–e) per group. Statistical analysis was performed with unpaired T-test (b, i, j), Gehan-Breslow-
Wilcoxon test (g) and two-way Anova (c–e, h, k, l). Data are reported as mean ± SEM; *p < 0.05, **p < 0.01
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apoE KO BM to WT (those presenting a faster allograft rejection),
compared to WT BM to apoE KO and WT BM to WT
(Fig. 2e–h). These data suggest that rejection was driven by apoE
deﬁciency in the hematopoietic compartment, irrespectively of
the genetic background of the recipient, and also support the
hypothesis that this effect might selectively apply to CD4+ T-cell
priming.
DC-derived apoE affects the adaptive immune response. To
further deﬁne the cellular source of apoE involved in the immune
phenotype of apoE KO mice, we analyzed its expression among
different subsets of leukocytes compared to the liver. Substantial
expression of apoE was observed not only in macrophages but
also in DCs (both spleen-derived DCs and bone marrow
derived DCs, BMDCs) while it was almost undetectable in T cells
(Fig. 3a, b). As DCs of both donor and recipient origin are
responsible for the initiation of direct and indirect alloresponses,
respectively39, we investigated whether apoE deﬁciency impacted
DC antigen presentation ability and induction of a primary
immune response by T cells. An allogeneic mixed lymphocyte
reaction (MLR) was setup using responder Balb/c T cells stimu-
lated by WT or apoE KO C57BL/6 DCs. Spleen-derived DCs
isolated from apoE KO mice were more efﬁcient than those from
WT mice at inducing BALB/c CD4+ but not CD8+ T cell pro-
liferation (Fig. 3c–e). To further conﬁrm these results in a
nominal antigen-speciﬁc response, WT and apoE KO DCs were
pulsed with peptides speciﬁc for OTI or OTII T cells and co-
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Fig. 2 Hematopoietic deﬁciency of apoE promotes allograft rejection and allogenic T-cell expansion. a Graphic representation of skin allograft
transplantation experiment: a piece of tail skin from C57BL/6Kd donor was transplanted on the back of bone marrow transplanted (BMT) WT and apoE KO
(BMT) mice; graft survival was scored up to 3 weeks. b Percentage of graft survival following skin allotransplantation in BMT mice. Survival of <50% of
the donor skin was recorded as rejection. c Plasma cholesterol determination (mg/dL) after allograft rejection in BMT mice. d FPLC proﬁles of
cholesterol distribution in the different lipoprotein subclasses (VLDL, LDL and HDL) from pooled plasma of grafted BMT mice (n= 4 for each group). e and
g Proliferation of CD4+ (e) and CD8+ (g) lymphocytes isolated from draining lymph nodes of BMT-grafted mice, determined as Ki67+ staining following
challenge with splenocytes isolated from C57BL/6Kd donor. f and h Polarization of CD4+ (f) and CD8+ (h) lymphocytes isolated from draining lymph
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performed with Gehan-Breslow-Wilcoxon test (b) and two-way Anova (c, e–h). Data are reported as mean ± SEM; *p < 0.05, **p < 0.01
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cultured with OTI or OTII TCR-transgenic T cells (antigen
speciﬁc, non-mismatch-based assay). A signiﬁcantly increased
proliferation was observed in OTII T cells incubated with apoE
KO-pulsed DCs compared to WT-pulsed DCs, while OTI T-cell
proliferation was similar irrespective to the DC origin (Fig. 3f–h).
Moreover, OTII T cells incubated with apoE KO DCs displayed
increased production of IFNγ compared to those incubated with
WT DCs (Supplementary Figure 5A, B). In contrast, T cells
isolated from apoE KO mice underwent a similar rate of pro-
liferation compared to WT T cells when co-cultured with BALB/c
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spleen-derived DCs (Supplementary Figure 5C). In line with these
results, conjugates between BMDCs of BALB/c mice and T cells
from WT and apoE KO mice were similar in both naïve and
activated T cells, ruling out differences in cell:cell interactions due
to apoE deﬁciency in T cells (Supplementary Figure 5D). Finally,
phosphorylation of Akt, a downstream target of TCR/CD28 co-
stimulation, was comparable in T cells isolated from WT and
apoE KO mice (Supplementary Figure 5E). These results excluded
the possibility that apoE deﬁciency directly affects T-cell activa-
tion and proliferation while indicating a selective effect on DCs.
To test this hypothesis, we transplanted male WT and apoE KO
skin (a source of tissue-resident DCs) to female WT recipients
(Fig. 3i). This system was chosen as rejection depends on the
presentation of endogenously expressed, male-speciﬁc minor
histocompatibility antigen H-Y40,41, hence does not involve host-
derived female DCs as these do not express the endogenous HY
antigen. As shown in Fig. 3j, apoE deﬁciency in transplanted skin
signiﬁcantly reduced graft survival, indicating that lack of apoE
expression by graft-derived antigen presenting cells might be
responsible for enhanced allograft rejection.
ApoE deﬁciency affects DC antigen presentation function. The
data presented thus far indicate that apoE deﬁciency leads to
proliferation and preferential differentiation of CD4+ T cells
toward an effector phenotype, an effect dependent on DC activity.
Therefore, we sought to investigate the mechanism by which apoE
regulates DC antigen presenting function. An analysis of DC
distribution showed a signiﬁcant increase of CD11c+ DCs in the
spleen of apoE KO mice as compared to their WT littermates
(Fig. 4a, b), in line to what has been previously reported42.
Moreover, we demonstrated that within the DC population, the
conventional DC2 subset (cDC2: CD11c+MHCII+B220−CD11b
+CD8−) was signiﬁcantly increased in apoE KO compared to WT
mice (Fig. 4c), while no difference was observed in the
cDC1 subset (cDC1: CD11c+MHCII+B220+CD11b−CD8+)
(Fig. 4c) or in plasmacytoid DCs (CD11c+MHCII+B220+)
(Supplementary Figure 6A). Furthermore, MHC class II molecule
(MHC-II) surface expression was signiﬁcantly increased in cDC2
(the subset which more efﬁciently activate CD4+ T cells) from
apoE KO compared to WT mice (Fig. 4d and Supplementary
Figure 6L), while similar expression was observed on cDC1 cells
(Fig. 4d) which specialize antigen cross-presentation to CD8+
T cells. Of note, MHC class I molecule (MHC-I) expression was
similar in both cDC1 and cDC2 subsets (Fig. 4e). Likewise, the
distinct phenotype of apoE KO cDC2s was restricted to MHC-II
molecules as the expression of co-stimulatory molecules CD40,
CD86 and CD80 was comparable to WT DCs (Supplementary
Figure 6B-D). Consistent with this proﬁle, BMDCs derived from
WT and apoE KO mice presented a similar expression of CD86
and CD80 and production of IFNγ, IL-12, IL-23 and IL-10 fol-
lowing stimulation with LPS (Supplementary Figure 6E-I). These
ﬁndings suggest that apoE deﬁciency might be associated with
increased antigen presentation, but not co-stimulatory function.
To validate this hypothesis, we tested in vitro and in vivo antigen
uptake and presentation using the Eα green ﬂuorescence protein
(EαGFP)/YAe, a system which allows tracking of antigen uptake/
processing and presentation in situ43,44. In vitro, BMDCs from
apoE KO mice displayed a signiﬁcant increase in antigen uptake
(GFP positivity) and presentation (Eα:IAb complex positivity)
compared to WT (Fig. 4f). In vivo, after peritoneal injection of the
EαGFP antigen, DCs from apoE KO mice showed
increased uptake of EαGFP as compared to WT (Fig. 4g); in
addition, GFP+DCs from apoE KO mice also displayed higher
levels of MHC-II expression (Fig. 4h). These observations indicate
that apoE inﬂuences antigen processing and presentation by DCs.
ApoE impacts DC cholesterol homeostasis. We next inter-
rogated the molecular mechanisms responsible for this effect. It
has been reported that key receptors involved in hematopoietic
stem progenitors cell proliferation are enriched in lipid rafts and
their expression can be modulated by apoE upon cholesterol
mobilization from the membrane21. We therefore asked whether
this mechanism could also be operational in DCs and performed
detailed lipidomic analyses of WT and apoE KO spleen-derived
DCs. ApoE KO DCs displayed a signiﬁcant increase in cholesterol
and oxysterols, including 25-hydroxycholesterol (25-OH), 7β-
hydroxycholesterol (7β-OH) and 7-Keto-cholesterol (7-KETO)
levels, concomitant to a decrease in the levels of several phos-
pholipids (Fig. 5a, Supplementary Figures 7A and 8A, B). The
accumulation of cellular cholesterol in the DCs from apoE KO
mice was further conﬁrmed by ﬁlipin staining (Fig. 5b). As a
consequence of sterols accumulation, apoE KO DCs displayed a
decreased expression of genes involved in cholesterol and fatty
acid uptake (LDLR, CD36) and cholesterol synthesis (HMGCoA
reductase and 24-Dehydrocholesterol Reductase, DHCR24)
(Fig. 5c), while the protein levels of cholesterol 25-hydroxylase
(CH25H), the enzyme that catalyzes cholesterol conversion to 25-
OH, was signiﬁcantly higher in apoE KO DCs (Fig. 5d). Of note,
no differences were observed between WT and apoE KO DCs in
the expression of genes promoting cholesterol efﬂux (ABCA1 and
ABCG1) (Fig. 5c) as well as in lipid raft content and MHC-II
expression after LXR activation in WT and apoE KO BMDCs
(Supplementary Figure 7C, D); however, this is not surprising as
the level of the dominant LXR ligand45, namely desmosterol, was
slightly decreased in DCs from apoE KO compared to those from
WT mice (Fig. 5a, Supplementary Figure 7A). This is consistent
with reduced protein levels of 7-dehydrocholesterol reductase
(DHCR7, Supplementary Figure 7B), an enzyme involved in
desmosterol synthesis, detected in apoE KO compared to WT
DCs, thus perhaps reﬂecting a negative feedback on the choles-
terol biosynthetic pathway. Importantly, increased cholesterol
accumulation led to increased lipid rafts in apoE KO compared to
WT DCs (Fig. 5e). Accordingly, membrane expression of toll-like
receptor 4 (TLR4), a key receptor involved in DC signal trans-
duction located in rafts, was signiﬁcantly increased in apoE KO
DCs compared to WT (Fig. 5f); this effect, however, was unre-
lated to the LPS responsiveness which was similar in WT and
apoE KO DCs (Supplementary Figure 6). We therefore investi-
gated whether membrane cholesterol accumulation also affected
the distribution of receptors involved in antigen presentation,
such as MHC-II molecules, known to localize in lipid rafts46. We
observed an increased localization of MHC-II molecules in
lipid raft microdomains in apoE KO DCs as compared to WT
(Fig. 5g, h), further supporting the concept that apoE, through the
regulation of membrane lipid homeostasis, plays a physiological
role in controlling the surface distribution of MHC-II molecules,
thus ﬁnely tuning the modality of DC antigen presentation to
CD4+ T lymphocytes.
Monocyte-DC function is differently affected by human apoE.
To assess the effect of apoE in human DCs, we took advantage of
the presence of three common isoforms of apoE in humans
namely apoE2, apoE3, and apoE4 (with ε2, ε3, and ε4 allele fre-
quencies of about 7, 78, and 14%, respectively)47. ApoE3 is
considered the parent form and contains a Cysteine (Cys) at
positions 112 and an Arginine (Arg) at position 158, while apoE2
and apoE4 isoforms differ by amino acid substitutions of a Cys at
position 158 and Arg at position 112, respectively, causing
structural alterations which impact protein function48. As a
consequence, lipid-binding properties differ between isoforms
and result in higher afﬁnity of apoE4 for lipid particles, thus
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causing a better interaction with VLDL, but less efﬁcient with
HDL compared to apoE3 and apoE2 isoforms49. We performed
an immuno-metabolic phenotyping of carriers of apoE isoforms
identiﬁed in the PLIC study50,51 investigating both biochemical
parameters and immune signature. Plasma total and LDL cho-
lesterol proﬁles differed in apoE2 (ε2/ε3), apoE3 (ε3/ε3) and
apoE4 (ε4/ε3) carriers (Fig. 6a, b) while plasma levels of trigly-
cerides were similar (Fig. 6c and Supplementary Table 1).
Next, we investigated by ﬂow cytometry whether functional
alterations of apoE in carriers of the apoE4 isoform reﬂected a
different CD4+ T-cell subset distribution. ApoE4 carriers pre-
sented increased levels of circulating CD4+ TEM, while CD4+
Tnaive, CD4+ TCM and Treg cells were similar to those of apoE3
carriers (Fig. 6d–i and Supplementary Figure 9A). As in mice the
expansion of TEM cells was independent of plasma cholesterol, we
evaluated whether this phenotype in apoE4 carriers might arise as
a result of enhanced DC antigen presentation ability, by per-
forming a mixed lymphocyte reaction (MLR) between monocyte-
derived DCs (MDC) pulsed with LPS and naive CD4+ T cells in
autologous serum (Fig. 6j). With this experimental setting, apoE
is produced by DCs and also carried by subject’s lipoproteins.
ApoE4 MDCs induced the differentiation of signiﬁcantly more
CD4+ Tnaive cells toward the CD4+ TEM phenotype when com-
pared to MDCs from apoE3 and apoE2 carriers, while the pro-
portion of CD4+ TCM cells was similar in all carriers (Fig. 6k,
Supplementary Figure 9B, C). We also excluded a direct effect of
apoE isoform on T cells by performing MLR in the presence of
CD4+ Tnaive cells from a donor expressing the parent apoE3
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isoform, thus conﬁrming that incubation with apoE4 MDCs
results in increased CD4+ TEM differentiation (Supplementary
Figure 10A). Given the immunomodulatory role of HDL52, we
asked whether the decreased afﬁnity of apoE4 for HDL might
affect their ability to promote cholesterol efﬂux, thus causing an
alteration in intracellular cholesterol handling leading ﬁnally to a
polarization toward a pro-inﬂammatory immune phenotype.
Cellular cholesterol levels were indeed signiﬁcantly increased in
apoE4 MDCs compared to apoE3 and apoE2 MDCs (Supple-
mentary Figure 10B, C). We therefore performed a comprehen-
sive characterization of MDCs from apoE4 carriers compared to
apoE3 MDCs, as apoE2 and apoE3 isoforms have similar afﬁnity
for HDL. We observed that treatment of MDCs with LPS
increased lipid rafts enrichment in apoE4 carriers compared to
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apoE3 carriers (Fig. 7a). In addition, the expression of MHC-II
molecule HLA-DR, but not CD80, was signiﬁcantly increased in
apoE4 compared to apoE3 MDCs, regardless of LPS stimulation
(Fig. 7b, c). These data conﬁrmed that human carriers of the
apoE4 isoform with reduced ability to mobilize cholesterol display
increased CD4+ TEM biased differentiation as a consequence of
enhanced antigen presentation by DCs.
Restoration of cholesterol efﬂux improves apoE4 DC function.
In animal models, cholesterol efﬂux mediated by apoE
containing-nascent HDL from hematopoietic stem cell progeni-
tors has been shown to reduce membrane lipid rafts21, thus
dramatically affecting DC antigen presentation46. Therefore, we
explored whether the use of serum containing apoE3-HDL could
rescue the phenotype of apoE4 MDCs by culturing apoE4 DCs
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with medium supplemented with serum from apoE4 and apoE3
carriers. ApoE3 serum reduced the enrichment of lipid rafts
(Fig. 7d) and cholesterol (Fig. 7e, f) in the membrane of apoE4
MDCs, especially after LPS-induced maturation. Reduced lipid
rafts and cholesterol accumulation in apoE4 MDCs incubated
with a serum containing apoE3-HDL was associated with
decreased expression of HLA-DR (Fig. 7g), which resulted in
decreased CD4+ TEM development (Fig. 7h) compared to cells
treated with apoE4 serum. In addition, preliminary data indicate
that this approach might also affect the expression of cholesterol-
related and inﬂammatory genes (Fig. 7i), although experiments in
a larger number of carriers of different apoE isoforms will be
required to validate this ﬁnding. Collectively, these data suggest
that exogenously added apoE3 can prevent the pro-inﬂammatory
T-cell phenotype induced by human DCs from apoE4 carriers.
Discussion
Apolipoprotein E (ApoE) is a 34.2 kDa glycosylated protein,
mainly bound to plasma lipoproteins but also present on immune
cell membrane20, which plays a crucial role in cellular and sys-
temic cholesterol metabolism.
Here we show that apoE deﬁciency enhances T-cell activation
as a result of increased DC antigen presenting function, as a
consequence of lipid raft enrichment and enhanced MHC-II
molecule clustering on the DC membrane. In antigen presenting
cells (APCs), lipid rafts act as cholesterol-enriched specialized
microdomains where MHC-II molecules concentrate, optimizing
T-cell activation46,53. Lack of DC-produced apoE results in
impaired removal of cholesterol from the membrane and lipid
raft accumulation. As a consequence, apoE KO mice display
enhanced expansion of pro-inﬂammatory CD4+ T cells (CD44hi
and TEM) and enhanced skin allograft rejection. We show that
this response is independent of dyslipidemia—a well-known
factor promoting systemic inﬂammation, and previously hypo-
thesized to impact T-cell activity54,55 but rather the consequence
of apoE deﬁciency in bone marrow-derived antigen-presenting
cells. ApoE was previously shown to affect macrophage func-
tion56. Here we show that apoE is also produced by mature DCs
and its deﬁciency in myeloid cells recapitulates the phenotype
observed in apoE KO mice.
Cellular lipid homeostasis and inﬂammatory responses are
reciprocally regulated. Loss of this balance—as it occurs in
macrophages lacking the ABC transporters ABCA1 and ABCG1
—leads to accumulation of free cholesterol in plasma membrane
resulting in increased TLR cell surface concentration and
enhanced inﬂammatory responses to LPS57,58. Cholesterol accu-
mulation in cells activates LXR, which promotes its efﬂux to lipid-
poor apoA-I and favors the reverse transport of cholesterol to the
liver for elimination59. Furthermore, LXR deﬁciency results in
increased inﬂammation60, aberrant lymphocyte proliferation15
and impaired antigen presentation by B cells and DCs5. The anti-
inﬂammatory effects of LXR were recently proposed, at least in
macrophages, to be the consequence of ABCA1-dependent
changes in membrane lipid organization but not of LXR depen-
dent ABCG1 or apoE modulation61. However, LXR-dependent
repression of inﬂammatory gene expression in activated macro-
phages was also shown to be independent of cholesterol mod-
ulation and to rely on the inhibition of multiple NF-κB target
genes (COX-2, IκBα, IL-1β, MCP-1, IL-6 and IL-1-receptor
antagonist) after LPS, TNF-α, or IL-1β stimulation62. In line with
this report, our observation that the expression of two key target
genes of LXR (such as ABCA1 or ABCG1) is not increased in
DCs from apoE KO, broadens the scenario by demonstrating the
autocrine/paracrine role of apoE in controlling cellular choles-
terol homeostasis in DCs beyond the role of LXR. A neutral effect
on LXR pathway in apoE KO DCs might result from the balance
between increased oxysterols levels and decreased levels of des-
mosterol, the ﬁnal precursor of cholesterol63 and the dominant
physiological activator of LXR45,64.
Our data indicate that apoE controls DC function through a
mechanism which appears to be restricted to MHC-II molecule
compartmentalization on the cell surface. In B cells, antigen
uptake was shown to be dependent on lipid raft-mediated
endocytosis, and, more importantly, localization and inter-
nalization of MHC-I and MHC-II molecules in different
membrane domains, with MHC-II molecules showing a strong
co-clustering with lipid rafts65. Our observations expand these
ﬁndings to DCs showing that accumulation of lipid rafts due to
apoE deﬁciency leads to an increased EαGFP peptide uptake and
processing through MHC-II molecules, which speciﬁcally elicits a
CD4+ but not CD8+ T-cell activation. Consistently, apoE deﬁ-
ciency in DCs boosted CD4+ but not CD8+ T-cell proliferation,
further conﬁrming that the modulation of cellular cholesterol by
apoE impacts mainly MHC-II function. Further, in vitro inhibi-
tion of cholesterol biosynthesis perturbed raft composition
resulting in the alteration of antigen processing and presentation
to CD4+ T cells66, which depends on MHC-II peptide complex
clustering in DC lipid microdomains67.
Finally, we show the translational relevance of our ﬁndings by
demonstrating that DCs from human carriers of the apoE4 iso-
form present increased lipid rafts content. This might be the
consequence of a decreased ability of apoE4 isoform to mobilize
cholesterol from DCs compared to the WT apoE3 isoform, as
previously demonstrated in macrophages68. This, in turn, leads to
an enhanced antigen presentation mediated by HLA-DR, as well
as to increased polarization of CD4+ naive T cells toward the pro-
inﬂammatory effector memory phenotype when incubated with
mature DCs.
Previously, increased lipid rafts accumulation has also been
observed in monocytes of apoE4 carriers with severe sepsis and
has been associated with higher cytokine levels upon ex vivo
stimulation with TLR2, TLR4, or TLR5 ligands and increased
organ injury as compared to apoE3 carriers69 further supporting
the relevance of apoE in humans. Altogether, these ﬁndings point
Fig. 7 Lowering cellular cholesterol rescues the phenotype of apoE4 MDCs. a–c Median ﬂuorescence intensity (MFI) of lipid rafts (CTXb, a), HLA-DR
(b), CD80 (c) in immature (LPS−) and mature (LPS+) MDCs. d and e Relative quantiﬁcation of lipid rafts (CTXb, d) and free cholesterol (ﬁlipin, e) in
immature (LPS−) or mature (LPS+) apoE4 MDCs cultured with serum derived from an allogenic apoE4 donor as compared to an apoE3 donor. Data are
presented as relative expression compared to immature apoE4 MDCs cultured with serum from an allogenic apoE4 donor. f Determination (ng/µg) of
sterols and oxysterols by gas chromatography-mass spectrometry of mature (LPS+) apoE4 MDCs cultured with serum from an allogenic apoE4 or apoE3
donor. g Relative expression of HLA-DR in immature (LPS−) or mature (LPS+) apoE4 MDCs cultured with serum derived from an apoE4 donor as
compared to immature (LPS−) apoE4 MDCs cultured with serum from an apoE4 donor; data are presented as relative expression (calculated from HLA-
DR+ cells) compared to immature apoE4 MDCs cultured with serum from an apoE4 donor. h Differentiation of CD4+ T naive cells from a carrier of apoE3
isoform with allogenic mature (LPS+) apoE4 MDCs cultured with serum from an apoE4 or apoE3 donor. i Heat-map of lipid-related and inﬂammatory
genes in mature (LPS+) MDCs from apoE4 carriers cultured in the presence of serum from allogenic apoE4 or an apoE3 donor; data are presented as
relative to mean expression in apoE3 DCs (log2 scale). N= 4–6 per group. Statistical analysis was performed with two-way Anova. Data are reported as
mean ± SEM; *p < 0.05, **p < 0.01
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to a critical role for apoE in immune responses by supporting
cholesterol and lipid mobilization from cells to HDL, which have
been proposed to modulate the immune response52.
In summary, our study provides compelling evidence for a
physiological role of apoE in adaptive immune response through
the modulation of membrane cholesterol levels and lipid rafts
content in DCs. The restoration of cholesterol homeostasis fol-
lowing the administration of WT apoE3 rescues the activated
phenotype observed in apoE4 DCs by decreasing lipid rafts and
MHC-II abundance. These ﬁndings pave the way for the ther-
apeutic exploitation of apoE as a tool to modulate immune
responses.
Methods
Mice. All mice used in this study were between the ages of 8–12 weeks. Male and
female WT and apoE KO on the C57BL/6 background and BALB/c mice were
purchased from Charles River (UK and Italy). Heterozygous (apoE+/−) were
crossed and littermates apoE KO and WT were used. B6Kd mice, which express
H-2Kd molecules as a transgene on the C57BL/6 background70, Marylin female
mice 71and OTI and OTII transgenic mice were bred in house. Mice were housed
four per cages and kept in a temperature-controlled environment (20 ± 2 °C, 50 ±
5% relative humidity) with a 12-hour light/dark cycle in an air-conditioned room
and free access to food and water. The investigation conforms to the European
Commission Directive 2010/63/EU and was approved by the Ethical Committee
(Progetto di Ricerca 2012/02, Autorizzazione Ministeriale 1094/2016) and Home
Ofﬁce guidelines (PPL 70/7443) following approval by Queen Mary University of
London Ethics Committee.
Human samples. The Progressione della Lesione Intimale Carotidea (PLIC) Study
(a sub-study of the CHECK study) is a large survey of the general population of the
northern area of Milan (n= 2606)50,51, followed at the Center for the Study of
Atherosclerosis, Bassini Hospital (Cinisello Balsamo, Milan, Italy). The Study was
approved by the Scientiﬁc Committee of the Università degli Studi di Milano
(“Cholesterol and Health: Education, Control and Knwoledge—Studio CHECK
(SEFAP/Pr.0003)—reference number Fa-04-Feb-01) on February 4th, 2001. An
informed consent was obtained by participants of the study in accordance with the
Declaration of Helsinki.
Genomic DNA was extracted using Flexigene DNA kit (Qiagen, Milan, Italy) as
previously described51. Genotyping for the apoE isoforms was performed by
TaqMan allelic discrimination. Information on medical histories and ongoing
therapies were obtained; blood samples were collected from the antecubital vein for
the determination of lipid proﬁle, glucose levels, liver enzymes, leukocyte count and
T-cell subsets as previously described17,38,51,72. Clinical characteristics are
presented in Supplementary Table 1 (supplemental information). Mixed
lymphocyte reaction and DC characterization was conducted on a subgroup of
18 subjects, 6 carriers of each apoE2, apoE3 and apoE4 isoforms matched for age
and gender, these experiments were performed by a researcher blinded to the apoE
genotype.
Isolation of primary lymphocytes from murine lymphoid organs. Primary
lymphocytes were isolated from the lymph nodes and spleen of apoE KO and WT
littermates (the scientist was blinded of the mice genotype). Lymph nodes and
spleens removed and weighed. A uniform cell suspension was prepared by washing
in 2% FBS, 2 µM EDTA PBS (MACS buffer) and by mashing the lymph nodes and
spleens through a 70 µm cell strainer with 1 mL syringe plunger followed by
centrifugation at 500×g for 5 min. The supernatant was aspirated and 5 mL
(per mice) of red cell blood lysis buffer (Sigma-Aldrich, Cat#R7757) were added
for 5 min at 4 °C, to deplete all the red blood cells, washed, spin down at 600×g for
5 min and the supernatant was thrown away. Cells were suspended in 10 mL of
MACS buffer and counted.
Flow cytometry. All ﬂow cytometry antibodies were used at 1:100 dilutions unless
otherwise speciﬁed. For immunophenotyping 100 µL of cells suspension and/or
blood, or 1 × 106 were acquired with BD LSR Fortessa (Becton Dickinson) or
Novocyte 3000 (ACEA Biosciences). Antibodies used are listed in Supplementary
Table 2. The different gating strategies are presented in Supplementary Figure
11-15.
Puriﬁcation of CD11c+ DCs and T cells from lymphoid organs. CD11c+ DCs
and T cells were puriﬁed from lymph nodes and spleen of C57BL/6 WT and apoE
KO mice and BALB/c mice, while CD4+ OTII transgenic T cells and CD8+ OTI
transgenic T cells where isolated from the spleen of OTII and OTI TCR-transgenic
mice. CD11c EasySep™ Mouse CD11c Positive Selection Kit, EasySep™ Mouse T
Cell Isolation Kit, EasySep™ Mouse CD4+ and CD8+ T Cell Isolation Kit (StemCell
Technologies, Cat#18758, Cat#19851, Cat#19852 and Cat#19853) were used.
Proliferation was calculated by mitotic index, deﬁned as the ratio between the
number of T cells undergoing mitosis to the total number of plated T cells. The
index is calculated at each cell division from the sum of mitotic events adjusted for
the number of cell precursors.
Mixed lymphocyte reaction DCs. Puriﬁed T cells were stained with CellTrace™
Violet Cell Proliferation Kit (5 µM, Invitrogen™, Cat#C34557), incubated for 20
minutes at 37 °C in dark, diluted ﬁve times in warm media, washed and resus-
pended in warm media for 10 minutes. 4 × 105 T cells were cultured with 1 × 105
of puriﬁed DCs and plated with 200 µL of AIM V® Serum Free Medium (Thermo
Fisher Scientiﬁc, Cat#12055083) in 96-well plate (U-bottom wells) for 5 days at
37 °C with 5% of CO2. Cells were stained with PECF594-conjugated anti-mouse
CD4 (BD Biosciences, Cat#562285) and PerCP Cy5.5-conjugated anti-mouse CD8
(eBioscience, Cat#:45-0081-82) for ﬂow cytometric detection of proliferation.
Antigen-speciﬁc T-cell activation. Puriﬁed CD4+ OTII and CD8+ OTI trans-
genic T cells were stained with CFSE (SIGMA-ALDRICH, Cat#21888), incubated
for 10 minutes at RT in dark, diluted ten times in 2% FBS, 2 µM EDTA PBS
(MACS buffer), washed three times and resuspended in warm media. 1.5 × 105
CD4+ OTII or CD8+ OTI transgenic T cells were cultured with 7.5 × 104 of
puriﬁed DCs, previously pulsed with OTII or OTI peptide (10 µg/mL, OVA
323–339 and OVA 257–264 [InvivoGen]) for 30 min at 37 °C with 5% of CO2.
Cells were then plated with 200 µL of AIM V® Serum Free Medium (Thermo
Fisher Scientiﬁc, Cat#12055083) in the presence of IL-2 (10 U/mL, Peprotech,
Cat#200-02) in 96-well plate (U-bottom wells) for 4 days at 37 °C with 5% of CO2
and proliferation assessed by ﬂow cytometry. For cytokine secretion, after 4 days of
co-culture, transgenic OTII CD4+ T cells were pulsed with OTII peptide (1 µg/mL)
for 4 h at 37 °C with 5% of CO2 in the presence of Brefeldin A (1:1000, BD
Biosciences Cat#554724) and CD28 (5 µg/mL, BD Biosciences Cat#553295).
Cytokine staining was performed by ﬂow cytometry following the instructions
from the ﬁxation/permeabilization kit (BD Biosciences, Cat#554715), using the
Alexa Fluor 647-conjugated anti-mouse IFNγ (BD Biosciences, Cat#563727),
PECy7-conjugated anti-mouse IL-4 (BD Biosciences, Cat#560699), BV421-
conjugated anti-mouse IL-10 (BD Biosciences, Cat#563276), APC-Cy7-conjugated
anti-mouse IL-17A (BD Biosciences, Cat#560881).
Isolation and culture of bone marrow-derived DCs. Bone marrow-derived
dendritic cells (BMDCs) were generated by ﬂushing with PBS femors and tibia of
WT and apoE KO mice or BALB/c mice. Cells were dispersed with a 5 mL syringe
and pass through a 70 µm cell strainer, washed with PBS, spin down at 600×g for
5 min and suspended in 5 mL of Red Cell Blood Lysis Buffer (SIGMA-ALDRICH,
Cat#R7757) for 5 min at 4 °C to deplete all the red blood cells. Bone marrow cells
were washed twice in 2% FBS, 2 µM EDTA PBS (MACS buffer), counted and
plated in a six-well plate with AIM V® Serum Free Medium (Thermo Fisher
Scientiﬁc, Cat#12055083) with 20 ng/mL of GM-CSF (ImmunoTools,
Cat#12343125) for 7 days at 37 °C with 5% of CO2. Cells were washed with PBS
and reﬁlled with 20 ng/mL GM-CSF in AIM V® Serum Free Medium at day 3 and,
at day 6, treated for 18 h with LPS (10 ng/mL, Sigma-Aldrich, Cat#L2630) to induce
maturation. For LXR activation, WT and apoE KO matured BMDCs were treated
with the LXR agonist GW3965 (1 µM) overnight at 37 °C with 5% of CO2.
EαGFP assay. In vitro assay was performed with immature BMDCs at day 6
treated with EαGFP peptide (50 µg/mL) for 4 h at 37 °C with 5% of CO2. BMDCs
were then collected, washed twice with 2% FBS, 2 µM EDTA PBS (MACS buffer)
and stained with biotin-conjugated anti-mouse Eα 52–68 peptide (eBioscience,
Cat#13-5741-81), for 30 min at 4 °C. Cells were washed twice with 2% FBS, 2 µM
EDTA PBS (MACS buffer) and stained with APC-conjugated streptavidin
(eBioscience, Cat#17-4317-82) for 30 min at 4 °C. Antigen uptake and presentation
were assessed by ﬂow cytometry.
For in vivo assay, WT and apoE KO mice were injected i.p. with EαGFP peptide
(20 µg/mL). After 24 h, peritoneal lavage was collected, washed in 2% FBS, 2 µM
EDTA PBS (MACS buffer) and stained for ﬂow cytometry analysis with eFluor660-
CD11c (eBioscience, Cat#500114) and eFluor 450- MHCII (eBioscience, Cat#48-
5321-82).
Cytokine production. Cytokine production was assessed in BMDCs (day 6) treated
with LPS (10 ng/mL SIGMA-ALDRICH, Cat#L2630) for 4 h in the presence of
Brefeldin A (1:1000, BD Cat#554724). Cytokine staining was performed by ﬂow
cytometry following the instructions from the ﬁxation/permeabilization kit (BD,
Cat#554715), using the Alexa Fluor 647-conjugated anti-mouse IFNγ (BD,
Cat#563727), PECy7-conjugated anti-mouse IL-4 (BD, Cat#560699), BV421-
conjugated anti-mouse IL-10 (BD, Cat#563276), Alexa Fluor 647-conjugated anti-
mouse IL-23 (BD, Cat#565317), FITC-conjugated anti-mouse IL-12 (BD,
Cat#560564).
Bone marrow transplantation. WT and apoE KO mice were lethally irradiated
with a total dose of 900 cGy. Two hours later, mice were injected in the tail vein
with 5 × 106 nucleated bone marrow (BM) cells from WT or apoE KO donors.
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Recipient mice received gentamycin (0.4 mg/ml in drinking water) starting 10 days
before irradiation and maintained thereafter. At 10 weeks after BM transplantation,
Kd skin allograft transplantation was performed as described below.
Skin graft allotransplantation. Skin grafting was conducted using a method
previously described by Billingham and Medawar, 1951 using tail skin grafted onto
the lateral thorax. Donor tail skin was removed and cut into 1 cm2 sections. When
recipient mice reached a surgical plane of isoﬂurane anaesthesia, 0.26 µg of
Metacam (Boehringer Ingelheim GmbH) was injected s.c. Bandages were removed
7 days post transplantation and mice were observed for rejection for 3 weeks by an
observer blinded to the mice genotype.
Kd skin allograft. C57BL/6 WT and apoE KO littermates and bone marrow
transplanted WT and apoE KO mice (both males and females) received skin grafts
from female C57BL/6Kd mice.
Male skin allograft. C57BL/6 WT female received a C57BL/6 WT or apoE KO
male-derived skin graft.
Migration assay. Transwell 5 µm pore membranes (Corning®, Cat#CLS3421) were
used in the assay putting in the top chamber, a cell suspension of 300 µL of 0.6 ×
106 lymphocytes, isolated from draining lymph nodes of grafted mice, while in the
bottom chamber, a solution of 700 µL of R10 medium plus CXCL10 or CCL19/
CCL21 (200 ng/mL, Peprotech, Cat#250-27B and Cat#250-13). Cells were incu-
bated at 37 °C with 5% of CO2 and counted manually, with a counting chamber,
after 2, 4, 6 h.
Cholesterol determination and FPLC. Blood samples were collected in EDTA
tubes by intracardiac puncture and plasma was separated by high speed cen-
trifugation at 4 °C. For FPLC analysis, 200 μL pooled plasma (n= 4 mice total) was
separated on a Superose column (Amersham) at a ﬂow rate of 0.4 mL/min. Frac-
tions were collected and analyzed for total cholesterol quantiﬁcation by standard
enzymatic techniques using the Cholesterol CP Kit (ABX Pentra, Cat#A11A01634)
(Sala et al., 2014).
Lipidomic proﬁling of T cells and DCs. Lipidomic proﬁling of T cells and DCs
focused on phospholipids, fatty acids and sterols and was performed as described in
Cermenati et al. 2015. Out of 356 phospholipids were analyzed, including LysoPC:
lysophosphatidylcholine; PC: phosphatidylcholine; PC aa: phosphatidylcholine acyl-
acyl; PC ae: phosphatidylcholine acyl-alkyl also known as plasmalogens; PE:
phosphatidylethanolamine; PE aa: phosphatidylethanolamine acyl-acyl; PE ae:
phosphatidylethanolamine acyl-alkyl also known as plasmalogens; PS: phosphati-
dylserines; LysoPI: lysophosphatidylinositol; PI: phosphatidylinositol; PG: phos-
phatidylglycerol; LysoPA: lysophosphatidic acid; PA: phosphatidic acid; SM:
sphingomyelin; Cer: ceramide; GCer: glucosyl/galactosyl-ceramide; LacCer: lactosyl-
ceramide and gangliosides GM1, GM2 and GM3) 229 different species belonging to
different families were detected. Fifteen fatty acids were detected: palmitic acid
C16:0; palmitoleic acid C16:1; margaric acid C17:0; stearic acid C18:0; oleic acid
C18:1; linoleic acid C18:2; γ-linolenic acid C18:3; arachic acid C20:0; arachidonic
acid C20:4; eicosapentaenoic acid C20:5 (EPA); behenic acid C22:0; erucic acid
C22:1; docosahexaenoic acid C22:6 (DHA); lignoceric acid C24:0; nervonic acid
C24:1. Cholesterol, desmosterol and seven oxysterols (24-hydroxycholesterol, 25-
hydroxycholesterol, 27-hydroxycholesterol, 24,25-epoxycholesterol; 7α-hydro-
xycholesterol, 7β-hydroxycholesterol, 7-Keto-cholesterol) were detected.
Reagents. All HPLC solvents were mass spectrometry grade (Carlo Erba Reagents,
Italia). The internal standard for cholesterol and oxysterols quantiﬁcation was
cholesterol-2,2,3,4,4,6-d6 (SIGMA-ALDRICH) for fatty acids internal standards
were heneicosanoic acid (C21:0) and uniformly labeled 13C-linoleic acid (C18:2)
(SIGMA-ALDRICH). Phospholipid standards: C13:0 lysophosphatidylcholines
(LysoPC); C25:0 phosphatidylcholines (PC); C12:0 sphingomyelin (SM); 12:0–13:0
phosphatidylserine (PS); 12:0–13:0 phosphatidylinositol (PI); 12:0–13:0 phospha-
tidylglycerol (PG); 12:0–13:0 phosphatidic acid (PA); 12:0–13:0 phosphatidy-
lethanolamine (PE); C12 ceramide (Cer); glucosyl (β) C12 ceramide (GC); lactosyl
(β) C12 ceramide (LacCer); C17 mono-sulfo galactosyl(β) ceramide (D18:1/17:0;
GalCer) were purchased from Avanti Polar Lipids.
Phospholipid, FA, and cholesterol and oxysterol extraction methods. Internal
standards were added to samples, and lipid extraction was performed using the Folch
method [chloroform–methanol (MeOH) 2:1, v/v]. Samples were left overnight at 4 °C.
Then the organic residue was divided in two fractions: one for the analysis of
phospholipids (fraction A, 60% of the total sample), and the other for analysis of total
FAs, cholesterol and oxysterols (fraction B, 40% of the total sample). Total FAs,
cholesterol and oxysterols were obtained from samples by acid hydrolysis. Fraction B
was resuspended in chloroform–MeOH 1:1, v/v. 1M HCl:MeOH (1:1, v/v) was added
to the total lipid extract and shaken for 2 h. Then chloroform-water (1:1, v/v) was
added, and the lower organic phase was collected, split, transferred into tubes and
dried under nitrogen ﬂow. The residue was resuspended in 1mL of MeOH and split
60/40 for total FA and total cholesterol analysis, respectively.
Fatty acid and phospholipid proﬁle. For total fatty acid quantiﬁcation, aliquots of
each sample (10 μL) were diluted 1:10 in MeOH/water (50:50 v/v), transferred into
a 96-well-plate and placed in an auto-sampler for LC–MS/MS analysis. Quanti-
tative analysis was performed with calibration curves with pure standards
prepared and analyzed daily by electrospray ionization (ESI) using an API 4000
triple quadrupole instrument (AB Sciex, USA). The LC mobile phases were: water/
10 mM isopropylethylamine/15 mM acetic acid (phase A) and MeOH (phase B).
The gradient (ﬂow rate 0.5 ml/min) was as follows: T 0: 20% A, T 20: 1% A, T 25:
1% A, T 25.1: 20% A, T 30: 20% A. The Hypersil GOLD C8 column (100 mm ×
3mm, 3 μm) was maintained at 40 °C. The mass spectrometer was operated in
selective ion monitoring (SIM)/SIM mode. Data processing was performed using
MultiQuant software (AB Sciex, USA).
For the quantiﬁcation of the different phospholipids the MS analysis was
performed with a ﬂow injection analysis-tandem mass spectrometry (FIA-MS/MS)
method. The identity of the different phospholipid families was conﬁrmed using
pure standards, namely one for each family. Methanolic extracts were analyzed by a
3 min run in both positive and negative ion mode with a 268 multiple reaction
monitoring (MRM) transition in positive mode and 88 MRM transition in negative
mode. An ESI source connected with an API 4000 triple quadrupole instrument
(AB Sciex, USA) was used. The mobile phase was 0.1% formic acid in MeOH for
FIA positive analysis and 5 mM ammonium acetate pH 7 in MeOH for FIA
negative. MultiQuant™ software version 3.0.2 was used for data analysis and peak
review of chromatograms. Semiquantitative evaluation of phospholipids was
performed using MultiQuant software based on external pure standards.
Cholesterol and oxysterols quantiﬁcation. Fractions for the quantitative analysis
of total cholesterol and oxysterols, were analyzed by positive atmospheric pressure
chemical ionization (APCI+) using a linear ion trap-mass spectrometer (LTQ,
Thermo Fisher Co., San Jose, CA, USA) using nitrogen as sheath, auxiliary and
sweep gas. The instrument was equipped with a Surveyor liquid chromatography
(LC) Pump Plus and a Surveyor Autosampler Plus (Thermo Fisher Co., San Jose,
CA, USA). The mass spectrometer was employed in MS/MS mode using helium as
collision gas. The LC eluents were (phase A) acetonitrile (ACN)/methanol
(MeOH)/water (H2O) (76;20;4, v/v) and (phase B) propan-2-ol(IPA). The gradient
(ﬂow rate 1 ml/min) was as follows: T0 100% A, T15 100% A, T15.50% A, T35 50%
A, T35.50 100% A, T50 100% A. The Inertsil ODS-2 150 mm × 4.6 mm, 5 μm (GL
Sciences, Tokyo, Japan) column was maintained at 30 °C. Quantitative analysis was
performed on the basis of calibration curves with pure standards.
Quantitative real time PCR. NucleoSpin® RNA kit (Macherey-Nagel,
Cat#740955.50) was used to perform the RNA extraction from puriﬁed dendritic cells,
T cells, BMDCs, peritoneal macrophages and liver from WT and apoE KO mice
according to manufacturer’s instructions. The kit was also used for mRNA extraction
from human DCs of carriers of different apoE isoforms. RNA assessed for quality and
quantity using absorption measurements (NanoDrop™ 1000 Spectrophotometer,
Thermo Fisher Scientiﬁc) and transcripted in cDNA with iScriptTM cDNA synthesis
kit (BioRad). Gene expression analysis was performed using SYBR Green Supermix
(Thermo Fisher Scientiﬁc) in CFX connect light cycler (BioRad, Cat#1708841).
Expression was calculated using the ΔΔCt method (Livak and Schmittgen, 2001)
and normalized to a housekeeping gene (RPL for mouse genes and β-actin for
human genes). Primers for qPCR were designed with the help of online tools (https://
www.euroﬁnsgenomics.eu/). The thermal cycling proﬁle was a two-step ampliﬁcation
(95 °C for 5 min, followed by 45 cycles of 95 °C for 10 s and 55 °C for 30 s). The
sequences of the qPCR Primers are listed in Supplementary Table 3.
Fluorescence and confocal microscopy. Cells were allowed to adhere onto poly-L-
lysine coated coverslips and ﬁxed in 4% formaldehyde PFA (SIGMA-ALDRICH,
Cat#F8775) for 15 min at room temperature. Cells were then washed in PBS,
blocked in blocking buffer (PBS containing 5% BSA, SIGMA-ALDRICH) and then
stained with ﬁlipin (0.05 mg/mL SIGMA-ALDRICH, Cat#F9765) at 37 °C for 1 h,
CTXb (Cholera Toxin B subunit FITC conjugate—8 µg/mL, SIGMA-ALDRICH,
Cat#C1655) or appropriate primary antibodies (APC-conjugated anti-MHC Class
II I-A/I-E, eBioscience Cat#48-5321-82) at 4 °C for 30 min in the dark. Following
staining, cells were washed with PBS and coverslips were mounted onto slides using
Fluoroshield™ with DAPI (SIGMA-ALDRICH, Cat# F6182) and then examined
using a Zeiss microscope equipped with ×40 objective or Leica SP5 confocal
microscope equipped with a 63 × 1.4 NA objective.
Confocal images were acquired and analysed by Leica LAS software. Analysis of
ﬂuorescence intensity and co-localization was performed with ImageJ.
DC-T-cell conjugate analysis. Freshly isolated or 5 day-activated (with plastic-
bound anti-CD3/28 [eBioscience, Cat#16-0032-86 and Cat#16-0281-81] plus 50
U/mL IL-2 [Roche, Cat#16-0281-81]) lymphocytes from lymph nodes of WT and
apoE KO mice were stained with 1 µM CFSE (Sigma-Aldrich, Cat#21888), washed
three times in 2% FBS, 2 µM EDTA PBS (MACS buffer) and resuspended 106/mL.
Dendritic cells were cultured from bone marrow of BALB/c mice, collected after
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6 days, stained with 0.5 µM DDAO (Invitrogen, Cat#C34553) washed three times
in 2% FBS, 2 µM EDTA PBS (MACS buffer). 100 µL of lymphocyte suspension
(105 cells) were incubated with DCs at different ratio (1:3 and 1:5 DCs:T cells) for
15 min at 37 °C, gently resuspended and ﬁxed for ﬂow cytometry analysis.
pAKT phosphorilation. Puriﬁed T cells were plated 0.5 × 106 per well and allowed to
settle, then 1 µg/mL biotin labeled anti-CD3 and anti-CD28 (Thermo Fisher Scientiﬁc,
Cat#11456D) added for 5 min at 4 °C and crosslinked with strepatvidin (20 µg/mL).
At 1,5 and 15min time points 4% PFA was added to cell mixture and ﬁxed at 27 °C
for 15min. Cells were washed with PBS, permeabilized with 100% ice-cold methanol
and placed at −20 °C for 10min. Permeabilized cells were incubated in blocking
buffer (2% FCS/PBS+Na3VO4+NaF+NaCl) at RT for 30min. Cells were then
stained with BV605-conjugated anti-mouse CD4 (Biolegend, Cat#100547), PE-
conjugated anti-mouse CD8 (eBioscience, Cat#12-0081-82) and 1:150 diluted anti-
phospho-Akt (S473) (Cell Signaling Technology, Cat#9271) antibody for 30min at
RT. Cells were washed twice with PBS and stained with 1:4000 Alexa Fluor 647 Goat
anti-rabbit IgG (Life Technologies, Cat# A21245) at RT for 30min. Cells were washed
twice with PBS and resuspended in 200 µL PBS for cytoﬂuorimetric analysis.
Isolation and culture of MDCs and T cells from human blood. For human study,
15 mL of blood (supplemented with EDTA) were centrifuged for 12 min at 1000×g.
Plasma was discarded and the interface between plasma and red blood cells,
enriched in leukocytes and platelets (buffy coat), was carefully collected, diluted
with cold PBS and stratiﬁed on 3 mL of Ficoll-PlaqueTM PREMIUM (GE-
Healthcare, Cat#17-5442-03). After centrifugation of 35 min at 250×g, PBMC layer
was carefully collected and washed three times with 10 mL of cold PBS at 180×g for
12 min, to get rid of platelets. For MDCs growing, PBMC were plated in six-well
plate with AIM V® Serum Free Medium for 2 h at 37 °C and 5% CO2 to allow
adhesion of monocytes. Later, cells were washed twice with PBS at RT, and sus-
pended in AIM V® Serum Free Medium supplemented with 5% of autologous/
allogenic serum and GM-CSF (200 U/mL) and IL-4 (300 U/mL). After 5 days, LPS
(1 µg/mL, Sigma-Aldrich, Cat#L2630) was added and cells collected 48 h later. Cells
were washed in 2% FBS, 2 µM EDTA PBS (MACS buffer), and then stained with
ﬁlipin (0.05 mg/mL Sigma-Aldrich, Cat#F9765) at 37 °C for 1 h, CTXb (Cholera
Toxin B subunit FITC conjugate—8 µg/mL, Sigma-Aldrich, Cat#C1655) or FITC-
conjugated anti-human HLA-DR (BD, Cat#347363) or CD80 (BD, Cat#560926)
4 °C for 30 min in the dark. Following staining, cells were washed with 2% FBS,
2 µM EDTA PBS (MACS buffer) and analysed by ﬂow cytometry.
Naive CD4+ T cells were isolated from PBMC with Naive CD4+ T Cell
Isolation Kit II, human (Miltenyi Biotec, Cat#130-094-131).
Co-culture of T cells and MDCs. For human mixed lymphocyte reaction, CD4+ T
naive cells were co-cultured with autologous or allogenic monocyte-derived den-
dritic cells in AIM V® Serum Free Medium supplemented with 5% of allogenic
serum and GM-CSF (200 U/mL) and IL-4 (300 U/mL) at 37 °C with 5% of CO2.
After 3 or 5 days, cells were collected and stained for FITC-conjugated anti-human
CD45RA (BD Biosciences, Cat#555488) and PE-conjugated anti-human CCR7 (BD
Biosciences, Cat#552176).
Statistical analysis. Graph Pad-Prism6 was used for graphic presentation and
statistical analysis. Results are given as the mean per group ± SEM. The data were
analysed according to what reported in ﬁgure legends and a p-value of <0.05
was considered signiﬁcant. For comparison between two groups unpaired two-sides
T-test with a 95% conﬁdence interval was used; for multiple comparisons a regular
two-way ANOVA with a 95% conﬁdence interval was used.
The qPCR data were analyzed using the delta CT method by taking the CT
values of the genes of interest from the housekeeping gene following by
normalization to the wild type control sample.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its supplementary information ﬁles, or are
available upon reasonable requests to the authors. Further information and
requests for reagents may be directed to, and will be fulﬁlled by the corresponding
author Giuseppe Danilo Norata or by Fabrizia Bonacina (danilo.norata@unimi.it;
fabrizia.bonacina@unimi.it).
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